Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the field

Prithviraj Bose • 26 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms Pemigatinib

In this video, Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the recent approval of pemigatinib for the treatment of patients with relapsed/refractory (R/R) myeloid/lymphoid neoplasms with FGFR1 rearrangement. Dr Bose highlights the challenges of treating these patients and further explains the impact of this approval in the field. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Prithviraj Bose

2:55
Current and emerging treatments for MF: an update from ASH 2023
Prithviraj Bose • 11 Dec 2023
2:21
An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia
Prithviraj Bose • 11 Dec 2023
3:49
Bezuclastinib in adult patients with non-advanced systemic mastocytosis: initial results from Summit
Prithviraj Bose • 11 Dec 2023
3:30
LIMBER-104: zilurgisertib +/- ruxolitinib in patients with MF-associated anemia
Prithviraj Bose • 6 Sep 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals